U.S.
United Therapeutics jumps 12% on a patent win it hasn't filed with the SEC
United Therapeutics (patent ruling, +12.55%), Rogers (investor-day targets, +10.73%) and FormFactor (buy rating, +9.59%) rose on Sept. 30 for different reasons of different strength.